Uzel Şener Melahat, Akın Kabalak Pınar, Kavurgacı Suna, Yılmaz Demirci Nilgün, Kızılgöz Derya, Yanık Fazlı, Ermin Sinem, Söyler Yasemin, Karamustafaoğlu Yekta Altemur, Türkay Pakna Demet, Dumanlı Ahmet, Yılmaz Ülkü
Department of Chest Diseases, University of Health Sciences, Ankara Atatürk Sanatorium Training and Research Hospital, Keçiören, Ankara, Turkey.
Department of Chest Diseases, Faculty of Medicine, Gazi University, Ankara, Turkey.
Clin Transl Oncol. 2025 Jun;27(6):2750-2760. doi: 10.1007/s12094-024-03778-w. Epub 2024 Nov 5.
This study aimed to investigate the impact of oligometastasis and the M descriptor on survival in small cell lung cancer (SCLC).
This multicenter, retrospective study included patients with newly diagnosed extensive-stage SCLC(ES-SCLC) from 2010 to 2020. Subgroups: Group 1: single metastasis in a single organ, Group 2: 2-5 metastases in a single organ, Group 3: 6 or more metastases in a single organ, and Group 4: metastases in two or more organs. This classification was based on the 9th Staging-M descriptor. Three-year progression-free survival (PFS) and overall survival (OS) analyses were conducted.
The mean age of the 439 patients was 62 ± 10 years, and 89.5% of them were male. The mean PFS for Groups 1, 2, 3, 4 was 10.7 months (95% CI 8.9-12.5), 7.5 months (95% CI 5.6-9.4), 4.3 months (95% CI 2.9-5.7), and 5.4 months (95% CI 4.7-6.1), respectively. PFS in Group 2 was significantly higher. The mean OS for Groups 1, 2, 3, 4 was 13.3 months (95% CI 11.2-15.3), 9.5 months (95% CI 7.1-11.9), 7.1 months (95% CI 4.5-9.7), and 6.9 months (95% CI 6.0-7.9), respectively. OS in Group 1 was significantly higher. OS and PFS in the M1b group were significantly higher than in the M1c1 and M1c2 groups (p < 0.05) with no statistical difference between the M1c1 and M1c2 groups.
There is no significant difference in survival between the M1c1 and M1c2 groups. In ES-SCLC, the number of metastases may be a more predictive factor for prognosis than the number of metastatic organs.
本研究旨在探讨寡转移和M描述符对小细胞肺癌（SCLC）生存的影响。
这项多中心回顾性研究纳入了2010年至2020年新诊断的广泛期小细胞肺癌（ES-SCLC）患者。亚组：第1组：单个器官单一转移；第2组：单个器官2 - 5个转移灶；第3组：单个器官6个或更多转移灶；第4组：两个或更多器官转移。该分类基于第九版分期-M描述符。进行了三年无进展生存期（PFS）和总生存期（OS）分析。
439例患者的平均年龄为62±10岁，其中89.5%为男性。第1、2、3、4组的平均PFS分别为10.7个月（95%CI 8.9 - 12.5）、7.5个月（95%CI 5.6 - 9.4）、4.3个月（95%CI 2.9 - 5.7）和5.4个月（95%CI 4.7 - 6.1）。第2组的PFS显著更高。第1、2、3、4组的平均OS分别为13.3个月（95%CI 11.2 - 15.3）、9.5个月（95%CI 7.1 - 11.9）、7.1个月（95%CI 4.5 - 9.7）和6.9个月（95%CI 6.0 - 7.9）。第1组的OS显著更高。M1b组的OS和PFS显著高于M1c1和M1c2组（p<0.05），M1c1和M1c2组之间无统计学差异。
M1c1和M1c2组在生存方面无显著差异。在ES-SCLC中，转移灶数量可能比转移器官数量更能预测预后。
